» Articles » PMID: 26761210

The Role of PD-L1 in the Radiation Response and Prognosis for Esophageal Squamous Cell Carcinoma Related to IL-6 and T-cell Immunosuppression

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Jan 14
PMID 26761210
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to assess the significance of programmed cell death 1 ligand 1 (PD-L1) in esophageal squamous cell carcinoma (ESCC) and its association with IL-6 and radiation response. Weretrospectively enrolled 162 patients with ESCC, and examined the correlation between PD-L1 levels and clinical outcomes in esophageal cancer patients. Furthermore, the human esophageal SCC cell line CE81T and TE2 were selected for cellular experiments to investigate the role of PD-L1 in T cell functions and radiation response. Here we demonstrated that PD-L1 expression was significantly higher in esophageal cancer specimens than in non-malignant epithelium. In clinical outcome analysis, this staining of PD-L1 was positively linked to the clinical T4 stage (p=0.004), development of LN metastasis (p=0.012) and higher loco-regional failure rate (p=0.0001). In addition, the frequency of PD-L1 immunoreactivity was significantly higher in IL-6-positive esophageal cancer specimens. When IL-6 signaling was inhibited in vitro, the level of PD-L1 is significantly down-regulated. PD-L1 is a significant predictor for poor treatment response and shorter survival.As demonstrated through in vitro experiments, Irradiation increased PD-L1 expression in human esophageal cancer cells. The inhibition of T cell functions including proliferation and cytotoxicity against tumor cells might be the mechanisms responsible to the role of PD-L1 in radiation response. In conclusion, PD-L1 is important in determining the radiation response and could predict the prognosis of patients with esophageal SCC. Therefore, we suggest inhibition of PD-L1 as a potential strategy for the treatment of esophageal SCC.

Citing Articles

The Prognostic Value of Serum Soluble Programmed Death 1 (sPD-1) and Programmed Death Ligand 1 (sPD-L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis About Cohort Studies.

Yu Q, Li J, Mao W, Li Z, Li X, Li B Health Sci Rep. 2024; 7(11):e70178.

PMID: 39587995 PMC: 11586633. DOI: 10.1002/hsr2.70178.


Optimizing neoadjuvant radiotherapy for locally advanced esophageal squamous cell carcinoma: a comprehensive review on the role of concomitant or sequential immune checkpoint inhibitors.

Ghalehtaki R, Amini A, Abyaneh R Esophagus. 2024; 22(1):5-18.

PMID: 39562407 DOI: 10.1007/s10388-024-01097-1.


Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers.

Feghaly C, Challita R, Hadir H, Mobayed T, Bitar T, Harbi M Biomark Insights. 2024; 19:11772719241297168.

PMID: 39512649 PMC: 11542137. DOI: 10.1177/11772719241297168.


Biomarkers of lymph node metastasis in esophageal cancer.

Wu N, Cai J, Jiang J, Lin Y, Wang X, Zhang W Front Immunol. 2024; 15:1457612.

PMID: 39399490 PMC: 11466839. DOI: 10.3389/fimmu.2024.1457612.


Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma.

Kadono T, Yamamoto S, Kato K Future Oncol. 2024; 20(28):2097-2107.

PMID: 38861290 PMC: 11497952. DOI: 10.1080/14796694.2024.2345043.


References
1.
Mundy-Bosse B, Young G, Bauer T, Binkley E, Bloomston M, Bill M . Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011; 60(9):1269-79. PMC: 3521517. DOI: 10.1007/s00262-011-1029-z. View

2.
Pilones K, Vanpouille-Box C, Demaria S . Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol. 2014; 25(1):28-33. DOI: 10.1016/j.semradonc.2014.07.004. View

3.
Noh H, Hu J, Wang X, Xia X, Satelli A, Li S . Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal. 2015; 13:14. PMC: 4353689. DOI: 10.1186/s12964-015-0093-y. View

4.
Hu C, Hsieh H, CHIEN K, Wang P, Wang C, Chen C . Biologic properties of three newly established human esophageal carcinoma cell lines. J Natl Cancer Inst. 1984; 72(3):577-83. View

5.
Li S, Huang E, Lu H, Huang W, Yen C, Huang W . Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2012; 144(6):1352-9, 1359.e1. DOI: 10.1016/j.jtcvs.2012.06.049. View